Tag Archives: Samsung Biologics

June, 2018

January, 2016

  • 19 January

    Biogen-Samsung’s Enbrel Biosimilar Wins European Approval

    ZUG, Switzerland–(BUSINESS WIRE)–The joint venture between Biogen (NASDAQ:BIIB) and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI® , an etanercept biosimilar referencing Enbrel®i. BENEPALI has been granted marketing authorization in the European Union (EU) for the treatment of adults with moderate to severe rheumatoid arthritis …

November, 2015

  • 20 November

    EU Endorses Biogen and Samsung Bioepis’ Biosimilar Version of Enbrel

    ZUG, Switzerland–(BUSINESS WIRE)–Biogen (NASDAQ:BIIB) today announced further progress as part of its commitment to biosimilars. Samsung Bioepis, the joint venture between Samsung Biologics and Biogen, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the marketing authorization …